Buccal Drug Delivery System Market Report 2026

Buccal Drug Delivery System Market Overview

• Buccal Drug Delivery System market size has reached to $3.89 billion in 2025 • Expected to grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Rising Chronic Diseases Drives The Buccal Drug Delivery Systems Market • Market Trend: Increasing Focus On Product Launches To Provide Reliable Services To Their Customers • North America was the largest region in 2025.

What Is Covered Under Buccal Drug Delivery System Market?

The buccal drug delivery system refers to the injection of the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for administering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation. The main types of buccal drug delivery systems are sublingual, buccal tablets and lozenges, and oral sprays. The term sublingual refers to the route of administration for systemic medication delivery of the buccal drugs. These are used in various applications such as pain management, smoking cessation, and angina pectoris and are used by hospitals, ambulatory care centers, and others.

What Is The Buccal Drug Delivery System Market Growth Forecast?

The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing investments in transmucosal drug research, rising demand for smoking cessation therapies, expansion of personalized drug delivery systems, growing focus on compliance-friendly formulations, increasing development of novel buccal drugs. Major trends in the forecast period include increasing adoption of buccal and sublingual dosage forms, rising demand for rapid drug absorption systems, growing focus on patient-friendly drug delivery, expansion of controlled-release buccal formulations, enhanced emphasis on non-invasive therapies.

Global Buccal Drug Delivery System Market Segmentation

1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays 2) By Application: Pain Management, Smoking Cessation, Angina Pectoris 3) By End-User: Hospitals, Ambulatory Centers, Other End-Users Subsegments: 1) By Sublingual: Sublingual Tablets, Sublingual Films 2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges 3) By Oral Sprays: Spray Solutions, Spray Gels

What Is The Driver Of The Buccal Drug Delivery System Market?

The rising prevalence of chronic diseases is expected to propel the growth of the buccal drug delivery systems market going forward. Chronic diseases refer to ailments that persist for a year or longer, such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are the most prevalent chronic illnesses that can be managed but not cured and necessitate continuous nutrition and medical care. Buccal drug delivery systems provide appropriate and effective drug delivery for administering mucosal and transmucosal drugs that are required by several patients suffering from chronic diseases such as diabetes and cancer. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases drives the growth of the buccal drug delivery systems industry.

Key Players In The Global Buccal Drug Delivery System Market

Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc

Global Buccal Drug Delivery System Market Trends and Insights

Major companies operating in the buccal drug delivery systems market are focusing on product launches, such as melatonin oral spray, to drive revenues in their market. Melatonin oral spray is a form of melatonin supplementation that comes in a spray format for oral use. For instance, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, launched melatonin oral spray. The spray facilitates the body's natural production of melatonin, thereby improving sleep quality in an easy and effective way. This medication offers a quick fix for people who have trouble getting asleep, remaining asleep, or adjusting to different sleep regimens. The spray's quick and simple oral absorption allows for a quicker start to sleep and better quality of sleep.

What Are Latest Mergers And Acquisitions In The Buccal Drug Delivery System Market?

In April 2023, DifGen Pharmaceuticals LLC, a US-based Pharmaceutical company, acquired Aveva Drug Delivery Services Inc. for an undisclosed amount. This acquisition aims to give patients access to life-saving medications that are consistently high-quality and inexpensive. This acquisition allowed DifGen to increase its R&D and manufacturing capabilities and provide secure supply and complex dosage forms to its valued partners with local US-based manufacturing. Aveva Drug Delivery Services Inc. is a US-based company that provides buccal drug delivery systems.

Regional Outlook

North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Buccal Drug Delivery System Market?

The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.